Boehringer Ingelheim And Vitae Pharmaceuticals Announce A Major Collaboration To Research And Develop Novel Treatments For Alzheimer`s Disease
Boehringer Ingelheim and Vitae Pharmaceuticals, Inc., announced today that they have entered into a significant worldwide collaboration to research and develop beta-secretase (BACE) inhibitors for the treatment of Alzheimer"s disease. Current therapies for Alzheimer"s disease can improve symptoms, but do not affect the progression of the disease. The inhibition of BACE - an enzyme involved in the formation of amyloid-beta plaques which accumulate in the brains of patients with Alzheimer"s disease - offers the potential to slow or even halt disease progression.
Cardiovascular